Senate committee debates S.197 payment-reform bill as members warn it risks producing reports, not action

A Senate committee continued discussion of S.197 on the floor, focusing on whether the bill is a vehicle for meaningful primary care reform or merely another round of reports that will not be followed by action. Committee leaders scheduled a public hearing for the next day to gather broader input.

Several members said the bill as drafted feels "very reporty," warning that legislatures frequently commission studies without building political will or concrete follow‑through. "We have to be committed to being serious about following through on any reports that we require," one committee member said, urging clearer accountability and implementation language tied to the bill.

The committee reviewed core elements of the bill and its relationship to the existing Blueprint for Health. Members noted current Blueprint contributions come from commercial carriers such as Blue Cross Blue Shield, MVP and Cigna for their qualified plans, and from Medicaid, while Medicare stopped contributing after an earlier demonstration ended. The group discussed legal and technical limits on bringing self‑funded employer plans into state programs, noting federal preemption concerns and separate litigation tied to the all‑payer claims database.

Committee members debated the bill’s scope: is S.197 strictly payment reform, or does it aim to reframe primary care as a systemically supported public good? One participant summarized an aspirational goal voiced in the discussion: to "cultivate a system of care in which all patients have access to primary care without cost sharing," and to ensure providers can make a living while payers contribute fairly.

Quality measurement prompted a sustained exchange. Some members defended standardized measures as essential for accountability and accreditation, pointing to measures such as immunization and colorectal screening that have improved outcomes. Others countered that relying on narrow clinical metrics (for example, hemoglobin A1C targets for diabetes) risks distorting care, privileging larger organizations with administrative capacity, and failing to capture whole‑person care and social determinants. "We have to be careful about what we measure and how it shapes behavior," a committee member said, noting that measurement can advantage systems able to hire coders and administrators.

The committee also discussed targets for primary care spending (members cited various targets raised in testimony) and models that pool existing funds into a common fund or "public utility" for primary care. Advocates said pooling could reallocate current spending more equitably and expand who contributes; skeptics asked how targets would be enforced and whether the state has the political will to increase primary‑care shares of total spending.

Members repeatedly raised the loss of independent primary care practices and the administrative burdens that push clinicians toward employment by larger health systems. Several argued S.197 should prioritize simplifying administrative requirements and supporting smaller practices so primary care remains accessible and sustainable.

The committee did not vote on S.197 during the session. Members said they expect the public hearing to surface practical recommendations from patients, providers and other stakeholders. The committee paused to take testimony the following day, including on psychedelic medicine, which the chair announced as a separate item of interest.

What happens next: The committee will hold a public hearing the following day to solicit testimony; members said they want the Blueprint and staff to return with specific proposals and clearer implementation language before any formal vote.